Back to News
Market Impact: 0.1
Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts
Source: marketbeat.com
Healthcare & Biotech
Adagene Chairman, CEO and Co-Founder Peter Luo discussed the clinical-stage biotechnology company’s antibody pipeline, masked-therapy approach and upcoming development milestones, focusing on its T-cell engager portfolio. The article provides no specific trial results, milestone dates or numerical data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
ADAG0.15
More News
- Yields continue to rattle investors. These sectors are most at risk if rates stay elevated
- After years of U.S. export bans, China plans its own: 40 AI, chip and solar technologies could be restricted
- MapLight Therapeutics CMO Erin Foff sells $124,068 in stock
- William Blair initiates Revolution stock with outperform on RAS franchise
- Sickle cell gene therapies offer new hope, but access remains a major challenge
- Trump’s pharma holdings surged from $1.7 million in 2024 to $56.2 million as drugmakers gained Medicare exemptions, Democrats say
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience
- How to Build an Automated Research Process for a Fund